About   Help   FAQ
Mammalian Phenotype Ontology Annotations
Query Results - Summary
Symbol
Name
ID 		Nr3c1
nuclear receptor subfamily 3, group C, member 1
MGI:95824
141 phenotypes from 13 alleles in 23 genetic backgrounds
Export: Excel File
Allelic Composition
Genetic Background		 Annotated Term Reference
Nr3c1Gt(ESKN92)Hgs/Nr3c1+
B6.Cg-Nr3c1Gt(ESKN92)Hgs 		abnormal adrenal gland morphology J:141205
abnormal adrenal gland zona fasciculata morphology J:141205
abnormal adrenal gland zona glomerulosa morphology J:141205
abnormal circulating corticosterone level J:141205
normal adipose tissue phenotype J:141205
enlarged adrenal glands J:141205
normal growth/size/body region phenotype J:141205
normal homeostasis/metabolism phenotype J:141205
increased circulating aldosterone level J:141205
increased circulating angiotensinogen level J:141205
increased circulating corticosterone level J:141205
increased liver triglyceride level J:141205
increased renin activity J:141205
increased systemic arterial systolic blood pressure J:141205
normal renal/urinary system phenotype J:141205
Nr3c1Gt(ESKN92)Hgs/Nr3c1Gt(ESKN92)Hgs
B6.Cg-Nr3c1Gt(ESKN92)Hgs 		postnatal lethality, complete penetrance J:141205
Nr3c1tm1.1Jaci/Nr3c1tm1.1Jaci
Tg(Myh6-cre)2182Mds/0
involves: C57BL/6 * FVB/N 		abnormal atrial thrombosis J:201995
abnormal calcium ion homeostasis J:201995
abnormal heart echocardiography feature J:201995
abnormal lung morphology J:201995
abnormal myocardial fiber physiology J:201995
abnormal thoracic cavity morphology J:201995
cardiac fibrosis J:201995
cardiac hypertrophy J:201995
normal cardiovascular system phenotype J:201995
congestive heart failure J:201995
decreased heart left ventricle muscle contractility J:201995
dilated heart left ventricle J:201995
enlarged heart J:201995
heart inflammation J:201995
increased heart left ventricle weight J:201995
increased heart weight J:201995
increased myocardial fiber size J:201995
pathological neovascularization J:201995
poor circulation J:201995
premature death J:201995
respiratory distress J:201995
thick ventricular wall J:201995
Nr3c1tm1.1Jda/Nr3c1+
Tg(Lck-cre)548Jxm/0
B6.Cg-Nr3c1tm1.1Jda Tg(Lck-cre)548Jxm 		decreased thymocyte apoptosis J:189951
Nr3c1tm1.1Jda/Nr3c1tm1.1Jda
Tg(Lck-cre)548Jxm/0
B6.Cg-Nr3c1tm1.1Jda Tg(Lck-cre)548Jxm 		abnormal humoral immune response J:189951
decreased CD4-positive, alpha-beta T cell number J:189951
decreased CD8-positive, alpha-beta T cell number J:189951
decreased double-positive T cell number J:189951
decreased single-positive T cell number J:189951
decreased thymocyte apoptosis J:189951
thymus hypoplasia J:189951
Nr3c1tm1.1Mvc/Nr3c1+
Tg(Sim1-cre)1Lowl/0
involves: 129 * C57BL/6 * FVB 		abnormal hypothalamus physiology J:179918
decreased body weight J:179918
increased circulating adrenocorticotropin level J:179918
increased circulating corticosterone level J:179918
Nr3c1tm1.1Mvc/Nr3c1tm1.1Mvc
Tg(Sim1-cre)1Lowl/0
involves: 129 * C57BL/6 * FVB 		lethality, complete penetrance J:179918
Nr3c1tm1Dage/Nr3c1+
involves: 129P1/ReJ * C57BL/6 * C57BL/6J * SJL 		abnormal physiological response to xenobiotic J:147914
decreased adrenal gland zona fasciculata size J:147914
decreased B cell number J:147914
decreased circulating adrenocorticotropin level J:147914
decreased circulating corticosterone level J:147914
decreased circulating testosterone level J:147914
increased mean systemic arterial blood pressure J:147914
small adrenal glands J:147914
thin adrenal cortex J:147914
Nr3c1tm1Dage/Nr3c1tm1Dage
involves: 129P1/ReJ * C57BL/6 * C57BL/6J * SJL 		abnormal physiological response to xenobiotic J:147914
decreased adrenal gland zona fasciculata size J:147914
decreased B cell number J:147914
decreased CD4-positive, alpha-beta T cell number J:147914
decreased CD8-positive, alpha-beta T cell number J:147914
decreased circulating adrenocorticotropin level J:147914
decreased circulating corticosterone level J:147914
decreased circulating testosterone level J:147914
decreased macrophage cell number J:147914
increased mean systemic arterial blood pressure J:147914
small adrenal glands J:147914
thin adrenal cortex J:147914
Nr3c1tm1Gsc/Nr3c1tm1Gsc
involves: 129P2/OlaHsd 		abnormal adrenal chromaffin cell morphology J:54931
absent circulating adrenaline J:54931
decreased circulating noradrenaline level J:54931
decreased survivor rate J:54931, J:81588
neonatal lethality, incomplete penetrance J:81588
perinatal lethality, incomplete penetrance J:54931
respiratory failure J:81588
Nr3c1tm1Gsc/Nr3c1tm1Gsc
involves: 129P2/OlaHsd * 129/Sv 		abnormal alveolocapillary membrane morphology J:98065
abnormal lung development J:98065
abnormal lung morphology J:98065
abnormal pulmonary alveolus epithelial cell morphology J:98065
abnormal pulmonary alveolus morphology J:98065
abnormal surfactant secretion J:98065
decreased type I pneumocyte number J:98065
increased circulating corticosterone level J:98065
increased lung weight J:98065
increased type II pneumocyte number J:98065
perinatal lethality, complete penetrance J:98065
pulmonary hyperplasia J:98065
thick pulmonary interalveolar septum J:98065
Nr3c1tm1Gsc/Nr3c1tm1Gsc
involves: 129P2/OlaHsd * C57BL/6 		abnormal adrenal chromaffin cell morphology J:27441
abnormal adrenal cortex morphology J:27441
abnormal adrenal gland morphology J:27441
abnormal adrenal gland zona reticularis morphology J:27441
abnormal branching involved in terminal bronchiole morphogenesis J:27441
abnormal liver physiology J:27441
abnormal lung development J:27441
abnormal respiratory system development J:27441
absent adrenal medulla J:27441
absent adrenergic chromaffin cells J:27441
atelectasis J:27441
cyanosis J:27441
decreased adrenaline level J:27441
decreased noradrenaline level J:27441
enlarged adrenal glands J:27441
enlarged adrenocortical cell nuclei J:27441
enlarged adrenocortical cells J:27441
impaired lung alveolus development J:27441
increased adrenal gland zona fasciculata size J:27441
increased circulating adrenocorticotropin level J:27441
increased circulating corticosterone level J:27441
neonatal lethality, incomplete penetrance J:27441
respiratory distress J:27441
Nr3c1tm1Ljm/Nr3c1tm1Ljm
involves: 129S6/SvEvTac * C57BL/6 		abnormal lung development J:82174
abnormal lung morphology J:82174
abnormal thymocyte apoptosis J:82174
neonatal lethality, complete penetrance J:81588, J:82174
respiratory failure J:81588
thick pulmonary interalveolar septum J:82174
Nr3c1tm2.1Gsc/Nr3c1+
B6.129P2-Nr3c1tm2.1Gsc 		abnormal blood-brain barrier function J:137157
decreased T cell apoptosis J:126427
increased susceptibility to experimental autoimmune encephalomyelitis J:137157
Nr3c1tm2.1Gsc/Nr3c1tm2.1Gsc
involves: 129P2/OlaHsd 		abnormal adrenal chromaffin cell morphology J:54931
absent circulating adrenaline J:54931
decreased circulating noradrenaline level J:54931
decreased erythroid progenitor cell number J:58790
neonatal lethality, complete penetrance J:54931
Nr3c1tm2.1Gsc/Nr3c1tm2.1Gsc
involves: 129P2/OlaHsd * 129X1/SvJ 		abnormal osteoblast differentiation J:160669
abnormal osteoblast physiology J:160669
normal skeleton phenotype J:160669
Nr3c1tm2.1Ljm/Nr3c1tm2.1Ljm
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S6/SvEvTac 		abnormal interleukin-6 secretion J:197150
abnormal monocyte cell number J:197150
abnormal response to CNS ischemic injury J:197150
decreased susceptibility to neuronal excitotoxicity J:197150
increased interleukin-1 beta secretion J:197150
Nr3c1tm2.1Ljm/Nr3c1tm2.1Ljm
Tg(Camk2a-cre)T29-1Stl/0
involves: 129S6/SvEvTac * BALB/c * C57BL 		abnormal response to CNS ischemic injury J:197150
normal homeostasis/metabolism phenotype J:197150
normal nervous system phenotype J:197150
Nr3c1tm2Gsc/Nr3c1tm2Gsc
Lyz2tm1(cre)Ifo/Lyz2+
B6.129P2-Lyz2tm1(cre)Ifo Nr3c1tm2Gsc 		normal immune system phenotype J:137157
Nr3c1tm2Gsc/Nr3c1tm2Gsc
Lyz2tm1(cre)Ifo/Lyz2+
C.129P2-Lyz2tm1(cre)Ifo Nr3c1tm2Gsc 		normal skeleton phenotype J:160669
Nr3c1tm2Gsc/Nr3c1tm2Gsc
Tg(Alb1-cre)7Gsc/0
involves: 129P2/OlaHsd * FVB/N 		decreased body weight J:121556
Nr3c1tm2Gsc/Nr3c1tm2Gsc
Tg(Camk2a-cre/ERT2)2Gsc/0
involves: 129P2/OlaHsd * FVB/N 		increased circulating corticosterone level J:125230
Nr3c1tm2Gsc/Nr3c1tm2Gsc
Tg(Drd1a-cre)AGsc/0
involves: 129P2/OlaHsd * C57BL/6 * FVB/N 		abnormal behavioral response to addictive substance J:150544
abnormal nervous system electrophysiology J:150544
normal behavior/neurological phenotype J:150544
normal homeostasis/metabolism phenotype J:150544
Nr3c1tm2Gsc/Nr3c1tm2Gsc
Tg(Lck-cre)I57Jxm/0
B6.Cg-Nr3c1tm2Gsc Tg(Lck-cre)I57Jxm 		decreased physiological sensitivity to xenobiotic J:137157
decreased T cell apoptosis J:137157
increased susceptibility to experimental autoimmune encephalomyelitis J:137157
Nr3c1tm2Gsc/Nr3c1tm2Gsc
Tg(Nes-cre)1Kln/0
involves: 129P2/OlaHsd * C57BL/6 * SJL 		abnormal nervous system electrophysiology J:150544
Nr3c1tm2Gsc/Nr3c1tm2Gsc
Tg(Nes-cre)1Kln/0
involves: 129P2/OlaHsd * C57BL/6J * SJL 		abnormal adipose tissue distribution J:57315
abnormal fear/anxiety-related behavior J:57315
decreased anxiety-related response J:57315
decreased body length J:57315
decreased body size J:57315
decreased body weight J:57315
decreased bone mineral density J:57315
decreased circulating adrenocorticotropin level J:57315
normal endocrine/exocrine gland phenotype J:57315
hypersecretion of corticotropin-releasing hormone J:57315
increased adrenocorticotropin level J:57315
increased circulating glucocorticoid level J:57315
osteoporosis J:57315
Nr3c1tm2Gsc/Nr3c1tm2Gsc
Tg(Runx2-icre)1Jtuc/0
involves: 129P2/OlaHsd * FVB/N 		abnormal bone mineral density J:160669
abnormal bone ossification J:160669
abnormal osteoblast differentiation J:160669
decreased bone mineral density J:160669
decreased bone trabecula number J:160669
increased body length J:160669
increased bone trabecular spacing J:160669
normal skeleton phenotype J:160669
Nr3c1tm2Gsc/Nr3c1tm2Gsc
Tg(Slc6a3-icre)1Fto/0
involves: 129P2/OlaHsd * C57BL/6 * FVB/N 		normal behavior/neurological phenotype J:150544
normal homeostasis/metabolism phenotype J:150544
normal nervous system phenotype J:150544
Nr3c1tm2Gsc/Nr3c1tm2Gsc
Tg(Wap-cre)1Gsc/0
involves: 129P2/OlaHsd * FVB/N 		abnormal mammary gland alveolus morphology J:95548
abnormal mammary gland growth during pregnancy J:95548
Nr3c1tm2Ljm/Nr3c1tm2Ljm
Tg(Camk2a-cre)T50Stl/?
involves: 129 * BALB/c * C57BL/6 * CBA 		absent long-term depression J:96260
behavioral despair J:96260
decreased locomotor activity J:96260
increased circulating corticosterone level J:96260
Nr3c1tm2Ljm/Nr3c1tm2Ljm
Tg(Lck-cre)548Jxm/?
involves: 129S6/SvEvTac * C57BL/6 * CBA 		abnormal cecum morphology J:97484
abnormal interferon level J:97484
abnormal interleukin level J:97484
abnormal tumor necrosis factor level J:97484
cecum inflammation J:97484
increased susceptibility to endotoxin shock J:97484
increased susceptibility to induced morbidity/mortality J:97484
Nr3c1tm3Gsc/Nr3c1tm3Gsc
involves: 129P2/OlaHsd 		decreased erythroid progenitor cell number J:58790
Nr3c1tm3Gsc/Nr3c1tm3Gsc
involves: 129P2/OlaHsd * C57BL/6 		increased circulating corticosterone level J:67720
Nr3c1tm3Gsc/Nr3c1tm3Gsc
involves: 129P2/OlaHsd * FVB/N 		abnormal osteoblast physiology J:160669
normal skeleton phenotype J:160669
Nr3c1tm3Ljm/Nr3c1tm3Ljm
involves: 129S6/SvEvTac * FVB/N 		no abnormal phenotype detected J:98328
Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
11/12/2024
MGI 6.24 		The Jackson Laboratory